Overview

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

Status:
Recruiting

Trial end date:
2028-07-01

Target enrollment:

Participant gender:

Summary

LEVEL trial aims to demonstrate the higher efficacy of 177Lu-edotreotide over everolimus in patients with well to moderately differentiated neuroendocrine tumors of the lung and thymus who require systemic therapy. It is hypothesized that 177Lu-edotreotide may significantly increase the progression-free survival (PFS) compared to everolimus in lung and thymic carcinoids.

Phase:

Phase 3

Details

Lead Sponsor:

Grupo Espanol de Tumores Neuroendocrinos

Collaborators:

ITM Oncologics GmbH
MFAR

Treatments:

Edotreotide
Edotreotide lutetium LU-177
Everolimus